The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
- 31 May 2010
- journal article
- Published by Elsevier BV in Health Policy
- Vol. 95 (2-3), 216-228
- https://doi.org/10.1016/j.healthpol.2009.12.001
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Biotech acquisitions by big pharma: why and what is nextDrug Discovery Today, 2009
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Incentives for orphan drug research and development in the United StatesOrphanet Journal of Rare Diseases, 2008
- Biotech patents—business as usual?Nature Biotechnology, 2008
- Healthcare sustainability and the challenges of innovation to biopharmaceuticals in CanadaHealth Policy, 2008
- Market incentives and pharmaceutical innovationJournal of Health Economics, 2008
- Tier 4 Drugs and the Fraying of the Social CompactNew England Journal of Medicine, 2008
- Does orphan drug legislation really answer the needs of patients?The Lancet, 2008
- What's fueling the biotech engine?Nature Biotechnology, 2007
- Bush veto fuels orphan drug act uncertaintiesNature, 1990